{"disease":{"id":"chronic-lymphocytic-leucemia","name":"chronic lymphocytic leucemia"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT02401503","title":"Sequential Regimen of Bendamustine-Debulking Followed by ABT-199 and GA101-Induction and -Maintenance in CLL (CLL2-BAG)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":66,"lead_sponsor_name":"German CLL Study Group","has_results":false},{"nct_id":"NCT02345863","title":"Sequential Regimen of Bendamustin [B] Followed by GA101 and Ibrutinib [I] in CLL Patients","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":66,"lead_sponsor_name":"German CLL Study Group","has_results":false},{"nct_id":"NCT02445131","title":"Sequential Regimen of Bendamustine-Debulking Followed by CAL-101 and GA101-Induction and -Maintenance in CLL (CLL2-BCG)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":48,"lead_sponsor_name":"German CLL Study Group","has_results":false}],"total":3},"guidelines":[],"source":"Drug Landscape verified database"}